Cipla Limited, through its wholly-owned subsidiary Cipla Europe NV, has entered into a marketing alliance with the US-based BioQuiddity Inc for the European Union markets. Under the agreement, Cipla will sell BioQuiddity's anaesthetic products in certain European markets.
Cipla will launch the 'OneDose ReadyfusOR' pre-filled with Ropivacaine under its own label into the German market late this year.
Joshua Kriesel, president and CEO, BioQuiddity, said, “Cipla's strong commercial record puts them in an outstanding position to detail the OneDose ReadyfusOR's safety, sterility, and ease of use value proposition objectives."
Cipla will launch the 'OneDose ReadyfusOR' pre-filled with Ropivacaine under its own label into the German market late this year.
Joshua Kriesel, president and CEO, BioQuiddity, said, “Cipla's strong commercial record puts them in an outstanding position to detail the OneDose ReadyfusOR's safety, sterility, and ease of use value proposition objectives."